[go: up one dir, main page]

EA200100255A1 - НЕПЕПТИДНЫЕ СРЕДСТВА GnRH, СПОСОБЫ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ИХ ПОЛУЧЕНИЯ - Google Patents

НЕПЕПТИДНЫЕ СРЕДСТВА GnRH, СПОСОБЫ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ИХ ПОЛУЧЕНИЯ

Info

Publication number
EA200100255A1
EA200100255A1 EA200100255A EA200100255A EA200100255A1 EA 200100255 A1 EA200100255 A1 EA 200100255A1 EA 200100255 A EA200100255 A EA 200100255A EA 200100255 A EA200100255 A EA 200100255A EA 200100255 A1 EA200100255 A1 EA 200100255A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
nepeptide
gnrh
preparation
compounds
Prior art date
Application number
EA200100255A
Other languages
English (en)
Inventor
Марк Брайан Андерсон
Хареш Н. Вазир
Дейвид Роберт Лутин
Дженевив ДеГузман Пейдрес
Вед П. Пэтак
Лэнс Кристофер Кристи
Юфенг Хонг
Айлин Валензуэла Томпкинз
Хайтао Ли
Джеймс Фауст
Original Assignee
Агурон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Агурон Фармасьютикалз, Инк. filed Critical Агурон Фармасьютикалз, Инк.
Publication of EA200100255A1 publication Critical patent/EA200100255A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Описаны непептидные средства GnRH, способные к подавлению действия гормона, вызывающего выделение гонадотропинов. Эти соединения и их фармацевтически допустимые соли, мультимеры, пролекарства и активные метаболиты пригодны для лечения репродуктивных нарушений молочных желез и зависящих от стероидных гормонов опухолей, а также для регуляции фертильности, там где показано подавление выделения гонадотропина. Также описаны способы синтеза этих соединений и промежуточных веществ, требуемых для их получения.Отчет о международном поиске был опубликован 2000.11.16.
EA200100255A 1998-08-20 1999-08-20 НЕПЕПТИДНЫЕ СРЕДСТВА GnRH, СПОСОБЫ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ИХ ПОЛУЧЕНИЯ EA200100255A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9752098P 1998-08-20 1998-08-20
PCT/US1999/018790 WO2000020358A2 (en) 1998-08-20 1999-08-20 NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION

Publications (1)

Publication Number Publication Date
EA200100255A1 true EA200100255A1 (ru) 2002-02-28

Family

ID=22263796

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100255A EA200100255A1 (ru) 1998-08-20 1999-08-20 НЕПЕПТИДНЫЕ СРЕДСТВА GnRH, СПОСОБЫ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ИХ ПОЛУЧЕНИЯ

Country Status (33)

Country Link
EP (1) EP1105120B1 (ru)
JP (1) JP2002535244A (ru)
KR (1) KR20010085402A (ru)
CN (1) CN1379666A (ru)
AP (1) AP2001002053A0 (ru)
AT (1) ATE291423T1 (ru)
AU (1) AU759310B2 (ru)
BG (1) BG105362A (ru)
BR (1) BR9913374A (ru)
CA (1) CA2341346A1 (ru)
CZ (1) CZ2001523A3 (ru)
DE (1) DE69924387D1 (ru)
EA (1) EA200100255A1 (ru)
EE (1) EE200100102A (ru)
ES (1) ES2237966T3 (ru)
GE (1) GEP20043315B (ru)
HR (1) HRP20010206A2 (ru)
HU (1) HUP0103622A3 (ru)
ID (1) ID29244A (ru)
IL (1) IL141396A0 (ru)
IS (1) IS5846A (ru)
LT (1) LT4904B (ru)
LV (1) LV12732B (ru)
NO (1) NO20010309L (ru)
NZ (1) NZ509252A (ru)
OA (1) OA11599A (ru)
PL (1) PL356984A1 (ru)
SI (1) SI20746A (ru)
SK (1) SK2262001A3 (ru)
TR (1) TR200100631T2 (ru)
WO (1) WO2000020358A2 (ru)
YU (1) YU13701A (ru)
ZA (1) ZA200100831B (ru)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2133587C (en) * 1992-04-22 2008-11-18 Marcus F. Boehm Compounds having selectivity for retinoid x receptors
CA2368047A1 (en) * 1999-03-24 2000-09-28 Anormed Inc. Chemokine receptor binding heterocyclic compounds
AR024158A1 (es) * 1999-06-01 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
BR0210191A (pt) * 2001-06-06 2004-04-06 Agouron Pharma Agentes não peptìdicos da gnrh, composições farmacêuticas e métodos para o seu uso, e processos para os preparar e aos seus intermediários
AP1753A (en) 2001-06-11 2007-07-18 Shire Biochem Inc Thiophene derivatives as antiviral agents for flavvivirus infection
AU2002332099B2 (en) 2001-10-09 2007-12-13 Amgen Inc. Imidazole derivates as antiinflammatory agents
GB0126292D0 (en) * 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
JP2005170790A (ja) * 2002-01-09 2005-06-30 Ajinomoto Co Inc Ｎ−アルキルスルフォニル置換アミド誘導体
US6521395B1 (en) * 2002-01-30 2003-02-18 Eastman Kodak Company Infrared couplers for incorporating and recovering metadata
WO2003068769A1 (en) * 2002-02-12 2003-08-21 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
CA2489252A1 (en) 2002-06-13 2003-12-24 Pfizer Inc. Non-peptide gnrh agents, pharmaceutical compositions and methods for their use
US20060052344A1 (en) * 2002-11-20 2006-03-09 Montana John G Heterocyclic silicon compounds and their use in the treatment of diseases or conditions associated with gnrh (gonadotropin-releasing hormone)
CN101475528A (zh) * 2003-03-31 2009-07-08 大正制药株式会社 新的喹啉、四氢喹唑啉和嘧啶衍生物以及与其应用有关的治疗方法
US20050197350A1 (en) * 2003-03-31 2005-09-08 Taisho Pharmaceutical Co., Ltd. Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
EP1631560A2 (en) * 2003-04-25 2006-03-08 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
US7427683B2 (en) * 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
WO2004108133A2 (en) * 2003-06-05 2004-12-16 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
WO2005005443A1 (en) * 2003-07-09 2005-01-20 Paradigm Therapeutics Ltd. Organosilicon compounds and their use
RU2303594C2 (ru) * 2003-07-09 2007-07-27 Пэредайм Терапьютикс Лтд. Кремнийорганические соединения и их применение
BRPI0412446A (pt) 2003-07-10 2006-09-19 Paradigm Therapeutics Ltd compostos de silicio e seu uso
WO2005039564A1 (en) * 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
US20090291915A1 (en) * 2004-12-17 2009-11-26 Graham Andrew Showell Silicon Compounds and Their Use
US7569600B2 (en) 2005-05-13 2009-08-04 Virochem Pharma Inc. Compounds and methods for the treatment of prevention of Flavivirus infections
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
WO2006138304A2 (en) 2005-06-14 2006-12-28 Taigen Biotechnology Pyrimidine compounds
EP1896465A1 (en) * 2005-06-28 2008-03-12 Takeda Cambridge Limited Heterocyclic non-peptide gnrh antagonists
PT1910384E (pt) * 2005-08-04 2013-01-23 Sirtris Pharmaceuticals Inc Derivados de imidazo[2,1-b]tiazole como compostos moduladores da sirtuína
MX2008012482A (es) 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
WO2007131996A1 (en) * 2006-05-12 2007-11-22 Genmedica Therapeutics Sl Meta-xylylenediamine vanadate salts
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
AU2008310660A1 (en) * 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
CN101888991A (zh) 2007-10-31 2010-11-17 财团法人乙卯研究所 类视色素前体药物化合物
NZ588989A (en) 2008-04-21 2012-03-30 Taigen Biotechnology Co Ltd Heterocyclic compounds comprising pyrimidine, piperazine and amine.
UY31984A (es) * 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.
TW201021855A (en) 2008-11-13 2010-06-16 Taigen Biotechnology Co Ltd Lyophilization formulation
RU2013109143A (ru) 2010-08-05 2014-09-10 Амджен Инк. Бензимидазол- и азабензимидазолсодержащие соединения, которые ингибируют киназу анапластической лимфомы
CN102050823A (zh) * 2010-10-27 2011-05-11 华东理工大学 新型光稳定剂-鸟嘌呤类似物的合成及表征
WO2012112567A1 (en) * 2011-02-15 2012-08-23 Georgetown University Small molecule inhibitors of agbl2
JP6254075B2 (ja) 2011-05-16 2017-12-27 バイオノミックス リミテッド カリウムチャネル遮断剤としてのアミン誘導体
BR112014001518A2 (pt) * 2011-07-26 2017-02-14 Sanofi Sa derivados de ácido 3-heteroaroilamino-propiônico e seus usos como produtos farmacêuticos
EP2776411B1 (en) * 2011-11-07 2019-06-26 The University of Queensland Modulators of c3a receptors
EP2908811B1 (en) * 2012-10-17 2020-12-09 Exonate Limited Compounds useful for treating ocular neovascularisation
GB201300304D0 (en) * 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
WO2017070235A1 (en) * 2015-10-19 2017-04-27 Attenua, Inc. Antitussive compositions and methods
EP3679027A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
EP3935050B1 (en) 2019-03-06 2024-10-02 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3499002A (en) * 1968-06-20 1970-03-03 Robins Co Inc A H 1-carbamoyl-3-aroylpyrrolidines
NL6913261A (ru) * 1968-09-09 1970-03-11
US3932444A (en) * 1972-04-28 1976-01-13 E. I. Du Pont De Nemours & Co. 4-Imidazolylsulfonylimidazoles
US4013647A (en) * 1976-03-23 1977-03-22 American Home Products Corporation Morpholine containing tetrazole-5-carboxamide derivatives
GB1491776A (en) * 1976-09-08 1977-11-16 Pfizer Ltd Thiadiazoles
US4076718A (en) * 1977-01-21 1978-02-28 American Home Products Corporation 2,6-Pyridinediyl-bis-tetrazol-5-carboxamides
US5236928A (en) * 1991-03-19 1993-08-17 Merck & Co., Inc. Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
EP0592512A1 (en) 1991-07-01 1994-04-20 University Technologies International Inc. (Uti) NON-DESENSITIZING ANALOGS OF GnRH AND OTHER BIOLOGICALLY ACTIVE LIGANDS
WO1993013083A1 (en) * 1991-12-31 1993-07-08 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
DE69628705T2 (de) * 1995-08-24 2004-05-13 Basf Ag Isoxazole- und Isothiazole-5-carboxamid Derivate, deren Herstellung und deren Verwendung als Herbizide
CA2240111A1 (en) * 1995-12-14 1997-06-19 Wallace T. Ashton Antagonists of gonadotropin releasing hormone
JP2000511532A (ja) * 1996-05-20 2000-09-05 メルク エンド カンパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモンのアンタゴニスト
US5878393A (en) * 1996-09-09 1999-03-02 Matsushita Electric Industrial Co., Ltd. High quality concatenative reading system

Also Published As

Publication number Publication date
LT2001024A (en) 2001-11-26
YU13701A (sh) 2005-06-10
IS5846A (is) 2001-02-16
EP1105120B1 (en) 2005-03-23
WO2000020358A3 (en) 2000-11-16
AU2470900A (en) 2000-04-26
NO20010309L (no) 2001-04-11
ATE291423T1 (de) 2005-04-15
OA11599A (en) 2004-08-23
EP1105120A4 (en) 2001-12-19
ID29244A (id) 2001-08-16
IL141396A0 (en) 2002-03-10
WO2000020358A2 (en) 2000-04-13
PL356984A1 (en) 2004-07-12
HRP20010206A2 (en) 2004-02-29
CZ2001523A3 (cs) 2002-05-15
EP1105120A2 (en) 2001-06-13
NO20010309D0 (no) 2001-01-19
KR20010085402A (ko) 2001-09-07
HUP0103622A2 (hu) 2002-04-29
ES2237966T3 (es) 2005-08-01
SK2262001A3 (en) 2002-12-03
CN1379666A (zh) 2002-11-13
NZ509252A (en) 2004-05-28
BG105362A (en) 2001-12-31
CA2341346A1 (en) 2000-04-13
ZA200100831B (en) 2002-08-22
GEP20043315B (en) 2004-02-10
JP2002535244A (ja) 2002-10-22
LV12732B (en) 2002-03-20
WO2000020358B1 (en) 2001-01-04
AP2001002053A0 (en) 2001-03-31
AU759310B2 (en) 2003-04-10
HUP0103622A3 (en) 2003-01-28
EE200100102A (et) 2002-06-17
LT4904B (lt) 2002-04-25
LV12732A (en) 2001-10-20
TR200100631T2 (tr) 2002-08-21
DE69924387D1 (de) 2005-04-28
SI20746A (sl) 2002-06-30
BR9913374A (pt) 2001-05-15

Similar Documents

Publication Publication Date Title
EA200100255A1 (ru) НЕПЕПТИДНЫЕ СРЕДСТВА GnRH, СПОСОБЫ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ИХ ПОЛУЧЕНИЯ
LV12631A (en) Non-peptide gnrh agents
EA200201052A1 (ru) 8β-ГИДРОКАРБИЛЗАМЕЩЕННЫЕ ЭСТРАТРИЕНЫ В КАЧЕСТВЕ ЭСТРОГЕНОВ ИЗБИРАТЕЛЬНОГО ДЕЙСТВИЯ
ES2174129T3 (es) Antagonistas de la hormona de liberacion de la gonadotropina.
EA199900989A1 (ru) Нестероидные (гетеро)циклически замещенные ациланилиды, обладающие смешанным гестагенным и андрогенным действием
MXPA03001320A (es) Agentes no peptidicos de la gnrh, composiciones farmaceuticas y procedimientos para su uso.
ES8207120A1 (es) Un procedimiento para la preparacion de nuevos derivados transisomericos de 4-fenil-1,2,3,4-tetrahidro-1-naftalenami-na.
EA200000481A1 (ru) Производные гидроксамовой кислоты в качестве ингибиторов металлопротеаз матрикса (мпм)
PE55998A1 (es) Derivados 19-nor-pregneno substituidos
NO176437C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-aminotetralinderivater
EA200100750A1 (ru) Способ лечения сексуальных нарушений
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
ES2106616T3 (es) Derivados de 11,21-bisfenilo-19-nor-pregnanos.
NO20005145L (no) FremgangsmÕte for behandling av fertilitetsproblemer
WO2002098363A3 (en) NON-PEPTIDE GnRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM
EA200100828A1 (ru) 16-гидроксиэстратриены в качестве эстрогенов избирательного действия
IL145122A0 (en) C16 unsaturated fp-selective prostaglandin analogs
MX9303139A (es) Procedimiento para la preparacion de derivados esteroides 11-ceto.
EA200401544A1 (ru) 9α-ЗАМЕЩЁННЫЕ ЭСТРАТРИЕНЫ В КАЧЕСТВЕ ЭСТРОГЕНОВ ИЗБИРАТЕЛЬНОГО ДЕЙСТВИЯ
PT804186E (pt) Compostos alcaloides diterpenicos de indole
ES2139934T3 (es) Procedimiento mejorado para preparar derivados de cadena lateral de ciclohexapeptidil lipopeptidos.
EA200101180A1 (ru) Производные тио-оксиндола
EA201000097A1 (ru) 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов
CO4960661A1 (es) (17alfa)-17-hidroxi-11-metilen-19-norpregna-4,15-dieno-20- in-3-ona (org 30659) y su uso como anticonceptivo y en la terapia de sustitucion de hormonas
ES2054234T3 (es) Un procedimiento para la preparacion de derivados indol.